KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to 15.12%.

  • Travere Therapeutics' EBIT Margin rose 1043900.0% to 15.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.91%, marking a year-over-year increase of 1547200.0%. This contributed to the annual value of 138.88% for FY2024, which is 1283700.0% up from last year.
  • As of Q3 2025, Travere Therapeutics' EBIT Margin stood at 15.12%, which was up 1043900.0% from 11.05% recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' EBIT Margin peaked at 53.62% during Q4 2021, and registered a low of 336.53% during Q1 2024.
  • Its 5-year average for EBIT Margin is 164.08%, with a median of 125.11% in 2024.
  • In the last 5 years, Travere Therapeutics' EBIT Margin soared by 2861500bps in 2021 and then tumbled by -3491400bps in 2022.
  • Quarter analysis of 5 years shows Travere Therapeutics' EBIT Margin stood at 53.62% in 2021, then crashed by -651bps to 295.52% in 2022, then rose by 29bps to 209.13% in 2023, then skyrocketed by 61bps to 81.21% in 2024, then soared by 119bps to 15.12% in 2025.
  • Its EBIT Margin was 15.12% in Q3 2025, compared to 11.05% in Q2 2025 and 52.21% in Q1 2025.